Answers are grounded in this paper and cite their sources.
Earlier work by the author (12) showed that, while exposure measurements obtained from different institutions agreed to within ±3 per cent when cobalt-60 beams were used, discrepancy was greater when other energies were employed and still greater when the readings of these dosimeters were used in calculating the dose at depth. The author stated in that report: “While accurate comparisons of dosimeters and of exposure are essential, it is necessary to compare absorbed dose at depth for a given tumor dose prescription to make a co-operative project statistically meaningful.” Further work by Lescrenier (5, 6) supports this thesis. The present study was an attempt to find out whether the dose distribution that is actually delivered to patients (all of whom are being treated under the protocol of a national study) is in fact the same as the dose prescribed. The experiment was also designed to compare the medical interpretations of two radiographs and a biopsy report. Method and General Discussion Radiotherapists from 15 institutions taking part in a national clinical trial participated in this study. The radiotherapists and their institutions are referred to by number.2 Each institution in turn was sent two radiographs, a biopsy report, and a phantom to be “treated” in accordance with the instructions of the protocol. The phantom was usually shipped by air freight and was seldom kept in San Francisco for more than four working days. Institutions kept the phantom for periods varying from three days to six weeks; the average complete cycle time was one month. About 350 lithium fluoride capsules were placed throughout an Alderson Rando phantom (1) in a pattern designed to elicit as much information as possible throughout the largest volume that could conceivably be irradiated. Many dosimeters were also arranged in the “good” lung and in the inferior sections of the body to give an indication of leakage or scattered radiation outside the treatment beam. The radiographs used were postero-anterior and lateral films (Figs. 1 and 2) of a patient with poorly differentiated squamous cell carcinoma of the lung which had been proved by biopsy. The size of the obvious abnormality seen on the films (Figs. 1 and 2) was determined from knowledge of the magnification factors and skin markers, and a simulated wax lesion was implanted in the phantom to correspond to these abnormalities. The magnification factor on each of the two radiographs was stated so that the radiotherapist could use the clavicle as a reference point and locate the position of the implanted lesion in the phantom. It was assumed, at first, that the radiotherapist would take field films in accordance with the protocol (9). If his method of taking field films would add significantly to the dose, then he could state the extra dose from this source. A typical field film is shown in Figure 3.
No takes yet. Share an insight, caveat, or question.
B. Ralph Worsnop (1968) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: